Originally published In Press as doi:10.1074/jbc.M005617200 on September 19, 2000
J. Biol. Chem., Vol. 275, Issue 50, 39734-39740, December 15, 2000
Fusarium oxysporum Fatty-acid Subterminal
Hydroxylase (CYP505) Is a Membrane-bound Eukaryotic Counterpart
of Bacillus megaterium Cytochrome P450BM3*
Tatsuya
Kitazume,
Naoki
Takaya,
Norikazu
Nakayama
, and
Hirofumi
Shoun§
From the Institute of Applied Biochemistry, University of Tsukuba,
Tsukuba, Ibaraki 305-8572, Japan
Received for publication, June 27, 2000, and in revised form, September 13, 2000
 |
ABSTRACT |
The gene of a fatty-acid hydroxylase of the
fungus Fusarium oxysporum (P450foxy) was cloned and
expressed in yeast. The putative primary structure revealed the close
relationship of P450foxy to the bacterial cytochrome P450BM3, a fused
protein of cytochrome P450 and its reductase from Bacillus
megaterium. The amino acid sequence identities of the P450 and
P450 reductase domains of P450foxy were highest (40.6 and 35.3%,
respectively) to the corresponding domains of P450BM3. Recombinant
P450foxy expressed in yeast was catalytically and spectrally
indistinguishable from the native protein, except most of the
recombinant P450foxy was recovered in the soluble fraction of the yeast
cells, in marked contrast to native P450foxy, which was exclusively
recovered in the membrane fraction of the fungal cells. This difference
implies that a post (or co)-translational mechanism functions in the
fungal cells to target and bind the protein to the membrane. These
results provide conclusive evidence that P450foxy is the eukaryotic
counterpart of bacterial P450BM3, which evokes interest in the
evolutionary aspects concerning the P450 superfamily along with its
reducing systems. P450foxy was classified in the new family, CYP505.
 |
INTRODUCTION |
Cytochromes P450 are widespread in nature and catalyze
monooxygenation along with a variety of other reactions (1-4). Despite the incomparable molecular diversity of the P450 superfamily, the
tertiary structure is considered to be well conserved among all members
(5, 6). This hypothesis is now being proven by an increasing body of
knowledge of their crystal structures (7-12). The species P450nor and
P450foxy were originally isolated from the fungus Fusarium
oxysporum (13, 14). Both are unique in that they are
self-sufficient, which means that they can complete their functions
without the aid of other proteinaceous components such as
NADPH-cytochrome P450 oxidoreductase (referred to as P450 reductase).
P450nor functions as nitric-oxide reductase, taking part in the process
of fungal denitrification. Its self-sufficient nature depends on its
ability to receive electrons directly from NAD(P)H (13). In contrast to
the unique reaction of P450nor, P450foxy catalyzes the subterminal
(
-1 to
-3) hydroxylation of fatty acids (14) that seems to
be a standard P450-dependent monooxygenase reaction,
whereas it is also unusual because of its self-sufficient nature.
P450foxy was suggested to be a fused protein of P450 and its reductase;
and thus, the electrons from NADPH should transfer to the active-site
heme via its putative reductase domain (14).
Fatty acid (or alkane) terminal (
) and subterminal (in-chain;
-1,
-2, etc.) hydroxylations occur widely in nature and are catalyzed by
multicomponent monooxygenase systems. The "terminal oxidases" of
the bacterial systems except P450BM3 are of the non-heme iron type
(15), whereas those of eukaryotes are of the P450 type (1, 4, 16). The
physiological significance of the terminal (
) hydroxylation of
alkanes in bacteria and yeast is to utilize alkanes as carbon and
energy sources via the
-oxidation of fatty acids that are formed by
the successive oxidation of alkanes (17). On the other hand, the
physiological roles of the terminal hydroxylation of fatty acids
including those of P450BM3 and P450foxy are essentially unknown.
In-chain hydroxylated fatty acids are located in cutins that protect
plants from microbial attack (18). A contribution of
P450-dependent fatty acid (eicosanoid) hydroxylation to the
control of the arachidonate cascade in mammals has been proposed
(1, 19).
P450BM3 (CYP102) of the bacterium Bacillus megaterium was
the first member of the superfamily that was found to be fused with its
reductase (20). P450foxy bears close resemblance to P450BM3 in terms of
self-sufficiency, molecular mass, high catalytic turnover, and other
enzymatic properties (14), suggesting that P450foxy is also a fused
protein. Furthermore, P450foxy reacts with polyclonal antibodies raised
against P450BM3 (14), indicating that they are quite similar. Limiting
proteolysis of P450foxy yielded two main polypeptides that were
separable on SDS-PAGE.1 Their
Mr values suggest that the two polypeptides are
derived from the P450 and reductase domains, respectively. Only the
polypeptide with the lower Mr that should have
been derived from the P450 domain reacted with the polyclonal
antibodies raised against P450BM3 (14). This indicated similarity
between the P450 domains of P450foxy and P450BM3. On the other hand,
the only difference between P450foxy and P450BM3 was in their apparent
intracellular localization. P450foxy was purified from the membrane
fraction after solubilization (14), whereas P450BM3 is a soluble protein.
Here, we cloned the P450foxy-encoding gene and expressed it in a
heterologous yeast host-vector system. The results showed close
relationships between not only the P450 domains, but also the reductase
domains of P450foxy and P450BM3, generating questions about the
molecular evolution of P450 and its reductase.
 |
EXPERIMENTAL PROCEDURES |
Microorganism Strains, Culture, and Media--
The F. oxysporum MT-811 fungal strain containing P450foxy (21) was the
source of DNA. Escherichia coli XL1-Blue MRA, Y1090, and
MV1190 were the host cells for
EMBL3, for
gt11, and for the
construction of plasmids, respectively. Saccharomyces
cerevisiae INVSc1 (Invitrogen) and its transformants were cultured
in 2% dextrose and 0.67% yeast nutrient base (Difco)
supplemented with 60 µg/ml L-leucine, 20 µg/ml
L-histidine, and 40 µg/ml L-tryptophan; YEPD
medium (1% yeast extract (Difco), 2% peptone (Difco), and 2%
dextrose); and YEPG medium (1% yeast extract, 2% peptone, and 2%
galactose). Recombinant P450foxy was produced by culturing yeast
transformants in 50 ml of YEPD medium in a 500-ml Erlenmeyer flask at
30 °C on a rotary shaker at 200 rpm. The cells were transferred 24 h later to YEPG medium and cultivated for >24 h under the same conditions.
Peptide Sequencing--
Purified P450foxy (150 µg) (14) was
resolved by SDS-PAGE, electroblotted onto a nitrocellulose membrane,
and digested with trypsin as described (22). After separation by
reverse-phase liquid chromatography, the amino acid sequences of the
tryptic peptides obtained were determined using a PerkinElmer
Life Sciences Procise 492 automated protein sequencer.
Isolation of the P450foxy-encoding Gene (CYP505)--
Total DNA
of F. oxysporum MT-811 (21) was the template for the
polymerase chain reaction (PCR) with the following degenerate oligonucleotide primers: FA, 5'-TTYACNGCNTTYGARGAYGA-3' (corresponding to FTAFEDE); FB, 5'-CCRTGN(C/G)(A/T)NGGNGCRTC-3' (corresponding to DAPSHG); FC, 5'-GAYGARCCNAAYTGGGG-3' (corresponding to DEPNWG); and
FD, 5'-ATRAAYTTRTCNGCRTCRTT-3' (corresponding to NDADKFI). The
first PCR used 200 pM FA and 200 pM FB as the
primers and 0.5 µg of total DNA as the template. Amplification
proceeded by denaturation at 94 °C for 10 min, followed by 30 cycles
of 94 °C for 0.5 min, 42 °C for 1 min, and 72 °C for 2 min and
extension at 72 °C for 10 min. The second PCR used the product of
the first PCR as the template and FC and FD as the primers under the
same conditions.
Total DNA of F. oxysporum MT-811 was partially digested with
Sau3AI, ligated to BamHI-digested
EMBL3,
packaged in vitro, and transfected into E. coli
XL1-Blue MRA. The resultant DNA library was screened by plaque
hybridization (23) using the PCR product obtained above (see Fig.
1A) as the probe. Nucleotides were sequenced by dideoxy
chain termination (24) using the LONG READIR Model 4200 automated DNA
sequencer (LI-COR, Inc., Lincoln, NE).
Southern Blot Analysis--
Southern blot analysis essentially
proceeded as described (23) using a nylon membrane
(Hybond-N+, Amersham Pharmacia Biotech). Probes were
labeled and hybridized; membranes were washed; and signals were
detected using the ECL nucleotide labeling and detection system
(Amersham Pharmacia Biotech).
Isolation of P450foxy cDNA--
A cDNA library of
F. oxysporum MT-811 (25) was screened by plaque
hybridization using the 1.4-kilobase pair SalI
fragment of CYP505 (see Fig. 1A) as the probe.
About 60% of the total cDNA that contained the 3'-end was obtained
by this procedure. The 5'-region of the CYP505 cDNA was
obtained by the rapid amplification of cDNA ends (RACE) as follows.
mRNA was purified from total RNA of F. oxysporum (21)
using an mRNA purification kit (Amersham Pharmacia Biotech).
cDNA was synthesized using a Marathon kit (CLONTECH, Palo Alto, CA). The 5'-end of the
cDNA was ligated to a 44-base adapter oligonucleotide (supplied
with the kit) that included annealing sites for primers AP1
(5'-CCATCCTAATACGACTCACTATAGGGC-3') and AP2
(5'-ACTCACTATAGGGCTCGAGCGGC-3'). PCR was performed with the
CYP505-specific primer 5'-2
(5'-TGTTTGCTTGATCTCCAAAGCGTAGTT-3') and primer AP1. The product was
used as the template for the second PCR using the nested primer 5'-1
(5'-AGGATCCGTCATAGTGAAATTGAAGTT-3') and primer AP2. The product was
subcloned into the pGEM®-T vector (Promega, Madison, WI)
and sequenced. The transcription initiation site was estimated
from the results of 5'-RACE using the Marathon kit and primer
R1(5'-CTGGGAACTTCCTCTTATGCTCAA-3').
Expression in Yeast and Purification of Recombinant
P450foxy--
The expression plasmid pYESfoxy was constructed as
follows. The product of reverse transcription PCR was used as
the template for PCR with the oligonucleotide primer YE1
(5'-GGGGTACCATGGCTGAATCTGTCC-3', corresponding to the amino terminus of
P450foxy) and primer 5'-1. The resulting PCR product was cloned into
pGEM-T, the KpnI-BamHI fragment of which was
ligated to the same restriction sites of pYES2 (Invitrogen) to generate
pYESfoxy1. The AatII-SphI fragment of the
CYP505 cDNA was inserted between the AatII
and SphI sites of pYESfoxy1 to generate pYESfoxy.
S. cerevisiae INVSc1 was transformed with pYES2 or
pYESfoxy using lithium acetate (26). Induced cells were harvested by centrifugation and suspended in 10 ml of 50 mM MES (pH 7.0)
containing 10% glycerol, 0.1 mM EDTA, and 1 mM
dithiothreitol. The cells were disrupted twice using a French pressure
cell press (30,000 p.s.i.) and then separated by centrifugation at
3000 × g for 10 min. The supernatant was fractionated
by centrifugation at 150,000 × g for 80 min and used
as the soluble fraction. The precipitate was solubilized with 0.15%
Emulgen 913 (Kao Co., Tokyo) and separated by centrifugation
at 150,000 × g for 80 min. The supernatant was used as
the membrane fraction. Recombinant P450foxy was purified over
DEAE-cellulose (DE52, Whatman) as described (14).
Preparation of F. oxysporum Cellular Fractions--
Mycelia of
F. oxysporum MT-811 were collected on filter paper and
disrupted as described (14). The cell-free extracts were fractionated
by centrifugation at 150,000 × g for 90 min into supernatant (soluble fraction) and precipitate (membrane fraction). The
membrane fraction was further solubilized in 0.5 M KCl or 0.15% Emulgen 913 on ice for 1 h. The fraction was again
separated by centrifugation at 150,000 × g for 90 min
to obtain the solubilized fraction (supernatant).
Western Blot Analysis--
Samples (10 µg of protein) were
resolved by SDS-PAGE and electroblotted onto nitrocellulose membranes
(Hybond-C, Amersham Pharmacia Biotech). The blot was analyzed using
2000-fold diluted anti-P450foxy antiserum raised against purified
recombinant P450foxy. Immunoreactive signals were detected by
chemiluminescence using the ECL detection system (Amersham Pharmacia
Biotech) according to the manufacturer's instructions.
Analytical Methods--
Absorption spectra were recorded using a
Beckman DU7500 spectrophotometer. Fatty-acid hydroxylase and
NADPH-cytochrome c reductase activities were measured as
described (14). P450 content was determined using an extinction
coefficient of 91 mM
1
cm
1 for the difference in absorbance between
450 and 490 nm (27). Protein content was determined using the
Bio-Rad protein assay reagent. The amino acid sequences of proteins
were aligned using GENETYX-MAC Version 10.1.1. A phylogenetic tree was
constructed using the ClustalW Version 1.5 multiple alignment program
(European Molecular Biology Laboratory).
 |
RESULTS |
Isolation of the P450foxy-encoding Gene (CYP505)--
Based on the
amino acid sequences of the tryptic peptides, four degenerate
oligonucleotide primers (FA, FB, FC, and FD) were designed for nested
PCR (28) against total DNA of F. oxysporum (Fig.
1A). A 920-base pair fragment
with a deduced amino acid sequence that contained portions of sequences
exactly the same as those of the tryptic peptides (Fig.
2) was specifically amplified. This
indicated that this fragment was derived from the gene for P450foxy.
The genomic DNA library was subsequently screened using the 920-base
pair fragment as a hybridization probe. One positive clone was selected
and sequenced. An entire open reading frame was found (Fig. 2). The
presence of five introns in the open reading frame was confirmed by
comparison with the cDNA. The results of 5'-RACE suggested that the
transcription should start at position
230 (Fig. 2). We deduced an
initiation codon at positions +1 to +3 because no potential initiation
codon was observed between positions
230 and +1, and the deduced
initiation codon was surrounded by the fungal consensus sequence
TCA(C/A)(A/C)ATG(G/T)C (29). The deduced amino acid sequence contained
the same sequences as those of the six tryptic peptides (Fig. 2). These
results indicate that the open reading frame codes P450foxy, and the
DNA region was designated as CYP505.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 1.
P450foxy-encoding gene
(CYP505) of F. oxysporum MT-811.
A, restriction map. The large arrow and
open boxes indicate the open reading frame of
CYP505 and the intron positions, respectively. Small
arrows represent positions and direction of primers. The PCR
product and the 1.4-kilobase pair (kbp) SalI
fragment are shown by bars. B, BamHI;
E, EcoRI; S, SalI;
H, HindIII. B, Southern blot. Total
DNA (10 µg) was digested with EcoRV (lane EV)
or PstI (lane P) and hybridized with the probe
(the 1.4-kilobase pair SalI fragment). The positions and
sizes of DNA markers ( DNA digested with HindIII) are
shown on the left.
|
|

View larger version (88K):
[in this window]
[in a new window]
|
Fig. 2.
Nucleotide and deduced amino acid sequences
of CYP505. Introns are indicated in
lowercase letters. The arrow indicates the
predicted transcription initiation site. Putative CAAT boxes and
poly(A)+ addition signal are underlined. Amino
acid sequences of tryptic peptides are indicated by boldface
underlining.
|
|
In the 5'-upstream region of CYP505, two CAAT sequences are
located at positions
359 to
356 and
534 to
531 (Fig. 2).
CYP102 of B. megaterium contains in its
5'-upstream region the Barbie box, which responds to barbitals to
induce transcription of the gene (30). However, no such sequence was
found in CYP505, consistent with our previous finding that
P450foxy is not induced by barbitals (14).
Total DNA of F. oxysporum was digested with EcoRV
or PstI (Fig. 1B) or KpnI (data not
shown) that do not digest CYP505 and hybridized with
the probe P450foxy cDNA. Only a single hybridization signal was
obtained from each blot, indicating that one copy of CYP505
is present in F. oxysporum MT-811.
Predicted Structure of P450foxy--
The deduced amino acid
sequence of CYP505 is composed of 1066 amino acid residues,
and its calculated Mr is 117,871, which agreed
well with that of purified P450foxy (118,000) estimated by SDS-PAGE
(14). Hydrophobic clustering analysis suggested that the primary
structure contained neither a membrane anchor sequence in its amino
terminus nor a long hydrophobic stretch in the internal regions (data
not shown), although P450foxy should be membrane-bound. The primary
structure of P450foxy can be divided into P450, P450 reductase, and
their linker domains from sequence alignment with P450BM3 (31) (Figs.
3 and 4). The N-terminal 475 amino acid
residues form the P450 domain, which contains the sequence FGNGKRACIG
(Fig. 3, boxed). This sequence is consistent with the
heme-binding motif
(F(G/S)XGX(R/H)XCXG) that
is strictly conserved in P450 (4, 32). The P450 domain also contains the conserved sequence AGHET (Fig. 3, boxed), which agrees
with the consensus sequence ((A/G)GX(E/D)T) around the
conserved Thr residue in helix I (32). Other residues
(Glu322 and Arg325) in the putative helix K
were also conserved in P450foxy.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 3.
Alignment of the deduced amino acid sequence
of the P450 domain of F. oxysporum P450foxy (FOXP)
with the sequence of the corresponding domain of B. megaterium P450BM3 (BMP). Identical amino acid residues
are marked with asterisks. Consensus sequences around the
conserved Thr residue in helix I, the heme-binding region, and highly
conserved amino acids are boxed. The predicted linker domain
is underlined.
|
|
We predicted that the carboxyl-terminal half comprising 571 amino acid
residues would form a P450 reductase domain. Its sequence showed an
overall similarity to those characteristic of P450 reductases (Fig.
4). Most of the consensus sequences or
amino acid residues conserved in P450 reductases (33), in particular
those forming the FAD-, FMN-, and NADPH-binding domains (Fig. 4,
boxed), are also highly conserved in P450foxy.

View larger version (84K):
[in this window]
[in a new window]
|
Fig. 4.
Alignment of the deduced amino acid sequence
of the P450 reductase domain of P450foxy (FOXR) with the sequences of
the reductase domains of B. megaterium P450BM3 (BMR)
and rat P450 reductase (NCRAT). Identical residues are shown by
asterisks. Predicted residues for flavins and
nucleotide-binding regions are boxed.
|
|
The alignment indicated that the linker domain would be formed with 20 amino acid residues between the P450 and reductase domains (Fig. 3,
underlined). This domain contains two Lys residues and many
other hydrophilic residues. This appeared to be consistent with our
previous finding (14) that the limiting tryptic digestion of P450foxy
yielded two polypeptides that would have arisen from the P450 and
reductase domains, respectively, as the result of cleavage at this domain.
Comparison of P450foxy with other Cytochromes P450 and P450
Reductases--
The primary structure of each domain of P450foxy was
compared with those of other cytochromes P450 and P450 reductases
(Table I). The degree of homology (amino
acid sequence identity) was highest (~40.6%) between the P450 domain
of P450foxy (referred to as FOXP) and the P450 domain of P450BM3
(referred to as BMP). In contrast, sequence identity to other
cytochromes P450 was <24%. The intimate relationship between FOXP and
BMP is also indicated in the phylogenetic tree of the P450 superfamily
(Fig. 5) that was constructed between
representative members from various organisms. In addition, FOXP and
BMP are more closely related to the CYP4 (34), CYP52 (35), and CYP86
(36) families, all of which catalyze fatty acid subterminal (or
terminal) hydroxylation, than to other families. These fatty-acid
hydroxylase cytochromes P450 form a cluster in the tree on the basis of
catalytic function rather than the phylogenetic relationship of the
organisms of their origins.
View this table:
[in this window]
[in a new window]
|
Table I
Amino acid sequence identities of the P450 and P450 reductase domains
of P450foxy (CYP505) to homologs of various origins
The respective accession numbers for P450 and P450 reductases are as
follows: human, PIR JX0331 and A33421; rat, PIR S01336 and A00402;
housefly, PIR A32157 and GenBankTM/EBI L19897; Arabidopsis
thaliana, GenBankTM/EBI Z97337 and PIR S21530 and S21531; S. cerevisiae, PIR B36395 and A41447; and B. megaterium,
PIR A34286.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
Phylogenetic relationship of the P450 domain
of P450foxy (FOXP) to other cytochromes P540. Each P450 is shown
by family number, followed by the abbreviated name of the organism of
origin: Fuox, F. oxysporum; Pspu,
Pseudomonas putida; Dome, Drosophila
melanogaster; Arth, Arabidopsis thaliana;
Cama, Candida maltosa; Some,
Solanum melongena; Hosa, Homo sapiens;
Caal, Candida albicans.
|
|
The sequence identity of the P450 reductase domain of P450foxy was
again the highest (35.3%) to the P450 reductase domain of P450BM3
(Table I) and much lower (~25%) to other P450 reductases. The extent
of the identity was similar (24.9%) to the reductase of S. cerevisiae, the most closely related organism to F. oxysporum listed in Table I. Therefore, the sequence identities of
both the P450 and P450 reductase domains of P450foxy are exceptionally high to the respective domains of P450BM3, although the reductase domains of P450foxy did not seem to react with the polyclonal antibodies to P450BM3 on Western blots (14). The sequence identity between the overall regions of P450foxy and P450BM3 is 37.3%. These
results indicate that P450foxy and P450BM3 originated from the same
ancient gene.
Recombinant P450foxy--
Expression of recombinant P450foxy
(rP450foxy) was examined using the S. cerevisiae host-vector
system. The transformed yeast cells harboring pYESfoxy produced a
spectrophotometrically detectable amount of P450, whereas those
harboring only the vector (pYES2) did not. Concentrations of 0.098 and
0.13 nmol of P450/mg of protein were recovered from both the soluble
and membrane fractions of the transformed cells, respectively, and at
an 80:20 ratio of the absolute amount. Recombinant P450foxy was
therefore recovered mostly (80%) in a soluble form, in contrast to its
native form, which was originally purified from the membrane fraction
of F. oxysporum. A specific signal was detected by Western
blotting at the predicted Mr of 118,000 in both
fractions (Fig. 6A). These recombinant proteins seemed to be correctly folded because lauric acid-dependent NADPH oxidase activity was also detected in
both fractions (900 and 2100 nmol of NADPH/min/nmol of P450,
respectively). The difference in the specific activity between the
fatty-acid hydroxylase activities recovered in the two fractions could
not be elucidated, whereas the recombinant protein seemed to be
somewhat stabilized by binding to the membrane. These results indicate that P450foxy is produced in a soluble form that is partially associated with membranes in yeast cells.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
Expression of recombinant P450foxy.
A, Western blot of rP450foxy. Soluble (lanes 1 and 3) and membrane (lanes 2 and 4)
fractions were prepared from the yeast transformants harboring pYES2
(lanes 1 and 2) and pYESfoxy (lanes 3 and 4). Protein was present at 10 µg/lane. B,
absorption spectra of partially purified rP450foxy in resting (ferric),
dithionite-reduced (ferrous), and carbon monoxide (CO)-bound
forms. Inset, CO difference spectrum (CO-bound minus
ferrous).
|
|
Recombinant P450foxy was solubilized from the membrane fraction and
then partially purified and characterized. The absorption spectra are
characteristic of those of P450foxy (Fig. 6B). Several kinetic parameters, such as the turnover of laurate hydroxylase activity, Km for NADH, and the turnover of
NADPH-cytochrome c reductase activity, determined using the
recombinant protein were indistinguishable from those determined using
the native protein (14) (Table II). Thus,
the exceptionally high catalytic turnover of native P450foxy as
compared with other P450 monooxygenases could be reproduced in the
recombinant protein. Furthermore, rP450foxy also exhibited the
phenomenon observed with native P450foxy (14) as well as P450BM3 (37):
its NADPH-cytochrome c reductase activity was enhanced in
the presence of the substrate to be hydroxylated (fatty acid) (Table
II). These results unequivocally demonstrate that the rP450foxy
expressed in the yeast system is spectrally and kinetically
indistinguishable from the native protein.
P450foxy Is a Membrane Protein--
Native P450foxy is assumed to
be a membrane-bound protein, but results have not been conclusive (14).
We examined this property by Western blotting using the anti-P450foxy
antiserum. As shown in Fig.
7A, a specific signal with an
Mr of 118,000 reacted to the antiserum in both
the cell-free extracts before fractionation and the membrane fraction,
but not in the soluble fraction of F. oxysporum. P450foxy
was partially released into the soluble fraction by washing the
membrane fraction with 0.5 M KCl and mostly solubilized by
0.15% Emulgen 913 (Fig. 7B). These results suggest that
P450foxy is loosely bound to the membrane. An immunoreactive signal was
undetectable in the soluble fraction of F. oxysporum (Fig.
7A, lane 3), in contrast to the yeast cells, in
which most of the rP450foxy was recovered in the soluble fraction (Fig.
6A). A mechanism missing in the yeast cells may act in the
original fungal cells to translocate P450foxy to membranes.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 7.
P450foxy is membrane-bound in the original
F. oxysporum cells. A, Western blot of
cell-free fractions of F. oxysporum using antibodies to
P450foxy. Lane 1, crude cell extract; lane 2,
membrane fraction; lane 3, soluble fraction. Protein was
present at 10 µg/lane. B, solubilization of P450foxy. The
membrane fraction (lane 2 in A) was incubated
with either 0.5 M KCl (lanes 1 and 2)
or 0.15% Emulgen 913 (lanes 3 and 4) and then
fractionated by centrifugation at 150,000 × g into
supernatant (lanes 1 and 3) and precipitate
(lanes 2 and 4).
|
|
 |
DISCUSSION |
In this study, we cloned the gene of P450foxy
(CYP505) of F. oxysporum and expressed it
in heterologous host yeast cells. The results provide conclusive
evidence that P450foxy is a fused protein of P450 and its reductase and
that it has a phylogenetically close relationship to P450BM3 of
B. megaterium as predicted (14), although they originated in
a eukaryote and in a prokaryote, respectively. Genomic analysis has
recently revealed that Bacillus subtilis contains two genes
encoding a protein that is closely related to P450BM3 (PIR accession
numbers A69975 and D69799), suggesting a wide distribution of
P450BM3 among the genera Bacilli. Our findings regarding P450foxy further demonstrate that this type of fused protein
would occur more often in nature across phyla than has been thought.
The phylogenetic relationships between the members of the P450
superfamily approximately agree with those between the source organisms
of each P450 (4, 16, 39). For example, prokaryotic cytochromes P450 are
clustered into a big branch that is separate from eukaryotic groups,
and most plant cytochromes P450 are also clustered. However, two
exceptions are known. Prokaryotic P450BM3 is classified in the same
eukaryotic group as the CYP4 and CYP52 families (4, 16), and P450nor of
F. oxysporum (CYP55) is classified in the group of
prokaryotic cytochromes P450 (16, 39). These relationships also appear
in Fig. 5. P450 may have emerged at a very early stage, possibly before
eukaryotic cells appeared (16, 40), and the cytochromes P450 associated
with steroidogenesis have retained the oldest functions of P450 (40). The recent finding of CYP51 (P45014DM) in prokaryotes (41, 42) has
afforded further evidence to support this hypothesis. The appearance of
fatty-acid (alkane) (sub)terminal hydroxylase cytochromes P450 in both
prokaryotes and eukaryotes that are grouped in the same branch in the
phylogenetic tree (4, 16) seems to indicate that P450 also acquired
this function at a very early time. However, the known fatty-acid
(alkane) terminal hydroxylases of prokaryotes are mostly dependent on
non-heme iron proteins (15), with the exception of P450BM3. The finding
of P450foxy in a eukaryote is therefore intriguing.
In addition to the P450 domain, the sequence identity of the P450
reductase domain of P450foxy is also exceptionally high to the
corresponding domain of P450BM3 among the reductases examined (Table
I). In contrast to the vast molecular diversity of P450, P450 reductase
is usually found as a single molecular species, except in plants, which
have two (43). P450 reductase of this type containing both FMN and FAD
is fundamentally found only in eukaryotes. Therefore, the genes for the
P450 and reductase domains of P450foxy and P450BM3 appear to have fused
after F. oxysporum and B. megaterium diverged.
This suggests a horizontal transfer of the fused gene between the
eukaryotic and prokaryotic cells that occurred as an evolutionary
event. Comparison of the reductase domains of P450foxy and P450BM3 with
more reductases will clarify the origin of the fused proteins, although
both the P450 and P450 reductase domains of the fused proteins seem to
have originated in eukaryotes. Whether or not F. oxysporum
contains an "usual" P450 reductase that is not fused with P450
requires investigation. The occurrence of another P450 reductase
species in F. oxysporum is possible because the fungus
should contain other P450 species, e.g. at least CYP51,
which is essential for the synthesis of steroids (40, 41).
We also expressed the P450foxy-encoding gene in the heterologous host
S. cerevisiae. The recombinant protein was catalytically and
spectrally indistinguishable from the native protein, except for the
fact that it was recovered mostly in the soluble fraction of the yeast
cells. The native protein was exclusively recovered from the membrane
fraction of fungal cells. We cannot yet explain why a small portion
(20%) of rP450foxy was recovered in the membrane fraction. The
Mr values of the native and recombinant protein species recovered in the soluble and membrane fractions were identical according to SDS-PAGE (Figs. 6 and 7). This does not necessarily rule
out the possibility that these protein species are not completely identical. However, removing a few amino acid residues from the N or C
terminus by post-translational proteolysis is unlikely to have rendered
most of the rP450foxy soluble because a small portion of the
polypeptide comprising only a few amino acid residues probably cannot
anchor the polypeptide to a membrane. The distribution of a small
portion of rP450foxy to the membrane fraction might have arisen from a
nonspecific interaction.
On the other hand, native P450foxy would be targeted and bound to the
membrane by a post (or co)-translational mechanism that functions in
the fungal cells, but does not work in the yeast cells, because it was
exclusively recovered in the membrane fraction of the fungal cells. The
protein may be modified by a hydrophobic moiety such as a fatty acid
(44) or a prenyl group (38). Such a modification is consistent with our
findings that native P450foxy was loosely bound to the membrane and
that the purified protein was inert against Edman degradation performed
using an automated peptide
sequencer,2 suggesting that
its N terminus is blocked. The mechanism that targets and binds
P450foxy to the membrane remains to be elucidated.
 |
FOOTNOTES |
*
This work was supported by PROBRAIN (Program for Promotion
of Basic Research Activities for Innovative Biosciences); a
grant-in-aid for scientific research from the Ministry of Education,
Science, Culture, and Sports of Japan; and the Sakabe Project (High
Energy Accelerator Research Organization, Tsukuba, Japan).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence reported in this paper has been submitted
to the DDBJ/GenBankTM/EBI Data Bank with
accession number AB030037.
Present address: Legume Physiology Laboratory, National
Agriculture Research Center, Tsukuba, Ibaraki 305-8666, Japan.
§
To whom correspondence should be addressed. Tel.: 81-298-53-4603;
Fax: 81-298-53-4605; E-mail: p450nor@sakura.cc.tsukuba.ac.jp.
Published, JBC Papers in Press, September 19, 2000, DOI 10.1074/jbc.M005617200
2
N. Nakayama and H. Shoun, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
PAGE, polyacrylamide
gel electrophoresis;
PCR, polymerase chain reaction;
RACE, rapid
amplification of cDNA ends;
MES, 2-(N-morpholino)ethanesulfonic acid;
rP450foxy, recombinant
P450foxy.
 |
REFERENCES |
| 1.
|
Omura, T.
(1999)
Biochem. Biophys. Res. Commun.
266,
690-698
|
| 2.
|
Yoshida, Y.
(1993)
in
Cytochrome P-450
(Omura, T.
, Ishimura, Y.
, and Fujii-Kuriyama, Y., eds), 2nd Ed.
, pp. 1-15, Kodansha, Tokyo
|
| 3.
|
Sono, M.,
Roach, M. P.,
Coulter, E. D.,
and Dawson, J. H.
(1996)
Chem. Rev.
96,
2841-2887
|
| 4.
|
Nelson, D. R.,
Koymans, L.,
Kamataki, T.,
Stegeman, J. J.,
Feyereisen, R.,
Waxman, D. J.,
Waterman, M. R.,
Gotoh, O.,
Coon, M. J.,
Estabrook, R. W.,
Gunsalus, I. C.,
and Nebert, D. W.
(1996)
Pharmacogenetics
6,
1-42
|
| 5.
|
Gotoh, O.
(1992)
J. Biol. Chem.
267,
83-90
|
| 6.
|
Nelson, D. R.,
and Strobel, H. W.
(1989)
Biochemistry
28,
656-660
|
| 7.
|
Poulos, T. L.,
Finzel, B. C.,
and Howard, A. J.
(1987)
J. Mol. Biol.
195,
687-700
|
| 8.
|
Ravichandran, K. G.,
Boddupalli, S. S.,
Hasemann, C. A.,
Peterson, J. A.,
and Deisenhofer, J.
(1993)
Science
261,
731-736
|
| 9.
|
Hasemann, C. A.,
Ravichandran, K. G.,
Peterson, J. A.,
and Deisenhofer, J.
(1994)
J. Mol. Biol.
236,
1169-1185
|
| 10.
|
Cupp-Vickery, J. R.,
and Poulos, T. L.
(1995)
Nat. Struct. Biol.
2,
144-153
|
| 11.
|
Park, S.-Y.,
Shimizu, H.,
Adachi, S.,
Nakagawa, A.,
Tanaka, I.,
Nakahara, K.,
Shoun, H.,
Obayashi, E.,
Nakamura, H.,
Iizuka, T.,
and Shiro, Y.
(1997)
Nat. Struct. Biol.
4,
827-832
|
| 12.
|
Williams, P. A.,
Cosme, J.,
Sridhar, V.,
Johnson, E. F.,
and McRee, D. E.
(2000)
Mol. Cell
5,
121-131
|
| 13.
|
Nakahara, K.,
Tanimoto, T.,
Hatano, K.,
Usuda, K.,
and Shoun, H.
(1993)
J. Biol. Chem.
268,
8350-8355
|
| 14.
|
Nakayama, N.,
Takemae, A.,
and Shoun, H.
(1996)
J. Biochem. (Tokyo)
119,
435-440
|
| 15.
|
McKenna, E. J.,
and Coon, M. J.
(1970)
J. Biol. Chem.
245,
3882-3889
|
| 16.
|
Gotoh, O.
(1993)
in
Cytochrome P-450
(Omura, T.
, Ishimura, Y.
, and Fujii-Kuriyama, Y., eds), 2nd Ed.
, pp. 255-272, Kodansha, Tokyo
|
| 17.
|
Kusunose, M.,
Kusunose, E.,
and Coon, M. J.
(1964)
J. Biol. Chem.
239,
1374-1380
|
| 18.
|
Salaün, J.-P.,
and Helvig, C.
(1995)
Drug Metab. Drug Interact.
12,
261-283
|
| 19.
|
Makita, K.,
Falck, J. R.,
and Capdevila, J. H.
(1996)
FASEB J.
10,
1456-1463
|
| 20.
|
Narhi, L. O.,
and Fulco, A. J.
(1986)
J. Biol. Chem.
261,
7160-7169
|
| 21.
|
Tomura, D.,
Obika, K.,
Fukamizu, A.,
and Shoun, H.
(1994)
J. Biochem. (Tokyo)
116,
88-94
|
| 22.
|
Aebersold, R. H.,
Leavitt, J.,
Saavedra, R. A.,
Hood, L. E.,
and Kent, S. B.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
6970-6974
|
| 23.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 24.
|
Sanger, F.,
Nicklen, S.,
and Coulson, A. R.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
5463-5467
|
| 25.
|
Kizawa, H.,
Tomura, D.,
Oda, M.,
Fukamizu, A.,
Hoshino, T.,
Gotoh, O.,
Yasui, T.,
and Shoun, H.
(1991)
J. Biol. Chem.
266,
10632-10637
|
| 26.
|
Ito, H.,
Fukuda, Y.,
Murata, K.,
and Kimura, A.
(1983)
J. Bacteriol.
153,
163-168
|
| 27.
|
Omura, T.,
and Sato, R.
(1964)
J. Biol. Chem.
239,
2379-2385
|
| 28.
|
Morrison, J. F. J.,
and Markham, A. F.
(1995)
in
PCR2: A Practical Approach
(McPherson, M. J.
, Hames, B. D.
, and Taylor, G. R., eds)
, p. 181, Oxford University Press, New York
|
| 29.
|
Ballance, D. J.
(1986)
Yeast
4,
229-236
|
| 30.
|
Liang, Q.,
He, J. S.,
and Fulco, A. J.
(1995)
J. Biol. Chem.
270,
4438-4450
|
| 31.
|
Ruettinger, R. T.,
Wen, L. P.,
and Fulco, A. J.
(1989)
J. Biol. Chem.
264,
10987-10995
|
| 32.
|
Graham-Lorence, S.,
and Peterson, J. A.
(1996)
FASEB J.
10,
206-214
|
| 33.
|
Wang, M.,
Roberts, D. L.,
Paschke, R.,
Shea, T. M.,
Masters, B. S.,
and Kim, J. J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
8411-8416
|
| 34.
|
Kimura, S.,
Hanioka, N.,
Matsunaga, E.,
and Gonzalez, F. J.
(1989)
DNA (N. Y.)
8,
503-516
|
| 35.
|
Ohkuma, M.,
Muraoka, S.,
Tanimoto, T.,
Fujii, M.,
Ohta, A.,
and Takagi, M.
(1995)
DNA Cell Biol.
14,
163-173
|
| 36.
|
Benveniste, I.,
Tijet, N.,
Adas, F.,
Philipps, G.,
Salaun, J. P.,
and Durst, F.
(1998)
Biochem. Biophys. Res. Commun.
243,
688-693
|
| 37.
|
Klein,
and Fulco, A. J.
(1994)
Biochim. Biophys. Acta
1201,
245-250
|
| 38.
|
Glomset, J. A.,
Gelb, M. H.,
and Farnsworth, C. C.
(1990)
Trends Biol. Sci.
15,
139-142
|
| 39.
|
Nebert, D. W.,
Nelson, D. R.,
Coon, M. J.,
Estabrook, R. W.,
Feyereisen, R.,
Fujii-Kuriyama, Y.,
Gonzalez, F. J.,
Guengerich, F. P.,
Gunsalus, I. C.,
Johnson, E. F.,
Loper, J. C.,
Sato, R.,
Waterman, M. R.,
and Waxman, D. J.
(1991)
DNA Cell Biol.
10,
1-14
|
| 40.
|
Nelson, D. R.,
and Strobel, H. W.
(1987)
Mol. Biol. Evol.
4,
572-593
|
| 41.
|
Aoyama, Y.,
Horiuchi, T.,
Gotoh, O.,
Noshiro, M.,
and Yoshida, Y.
(1998)
J. Biochem. (Tokyo)
124,
694-696
|
| 42.
|
Bellamine, A.,
Mangla, A. T.,
Nes, W. D.,
and Waterman, M. R.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
8937-8942
|
| 43.
|
Urban, P.,
Mignotte, C.,
Kazmaier, M.,
Delorme, F.,
and Pompon, D.
(1997)
J. Biol. Chem.
272,
19176-19186
|
| 44.
|
Grand, R. J. A.
(1989)
Biochem. J.
258,
625-638
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. A. Roberts, A. Celik, D. J. B. Hunter, T. W. B. Ost, J. H. White, S. K. Chapman, N. J. Turner, and S. L. Flitsch
A Self-sufficient Cytochrome P450 with a Primary Structural Organization That Includes a Flavin Domain and a [2Fe-2S] Redox Center
J. Biol. Chem.,
December 5, 2003;
278(49):
48914 - 48920.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. D. Thackray and A. Moir
SigM, an Extracytoplasmic Function Sigma Factor of Bacillus subtilis, Is Activated in Response to Cell Wall Antibiotics, Ethanol, Heat, Acid, and Superoxide Stress
J. Bacteriol.,
June 15, 2003;
185(12):
3491 - 3498.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Roberts, G. Grogan, A. Greter, S. L. Flitsch, and N. J. Turner
Identification of a New Class of Cytochrome P450 from a Rhodococcus sp.
J. Bacteriol.,
July 15, 2002;
184(14):
3898 - 3908.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.